Stockreport

FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

Alector, Inc.  (ALEC) 
Last alector, inc. earnings: 3/24 04:05 pm Check Earnings Report
PDF -Latozinemab is the most advanced progranulin-elevating candidate in development for FTD-GRN and has now become the first investigational medicine to receive a Breakthro [Read more]